638 related articles for article (PubMed ID: 2159373)
1. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
2. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
4. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
5. Regressing nude mouse grafts of Burkitt's lymphoma x lymphoblastoid cell hybrids show deregulation of the c-myc gene and expression of the EBV latent membrane protein.
Wolf J; Klevenz B; Pawlita M; Komitowski D; Moldenhauer G; zur Hausen H
Int J Cancer; 1991 Jan; 47(1):99-104. PubMed ID: 1702406
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
7. [Epstein-Barr virus and Burkitt's lymphoma].
Joab I
Med Trop (Mars); 1999; 59(4 Pt 2):499-502. PubMed ID: 10901854
[TBL] [Abstract][Full Text] [Related]
8. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
9. Selective loss of integrated Epstein-Barr virus genomes after long-term cultivation of Burkitt's lymphoma x B-lymphoblastoid cell hybrids due to chromatin instability at the integration site.
Wolf J; Jox A; Skarbek H; Pukrop T; Bartnitzke S; Pawlita M; Diehl V; Bullerdiek J
Virology; 1995 Sep; 212(1):179-85. PubMed ID: 7676627
[TBL] [Abstract][Full Text] [Related]
10. Establishment of Epstein-Barr virus-negative diffuse large cell lymphoma cell line with an 8;22 chromosomal translocation.
Ichinose I; Nakano S; Ohshima K; Mitsugi K; Anzai K; Shida T; Niho Y
Cancer Res; 1991 Oct; 51(19):5392-7. PubMed ID: 1913659
[TBL] [Abstract][Full Text] [Related]
11. Oncogene expression and immunoglobulin synthesis in a North American Burkitt (NAB-2) lymphoma cell line with a 8;22 chromosome translocation.
Popescu NC; Dahlberg JE; Ablashi DV; Monastier M; Bona CA; DiPaolo JA; Hooper WC; Swan DC
Oncogene Res; 1990; 5(4):295-303. PubMed ID: 1697668
[TBL] [Abstract][Full Text] [Related]
12. Local growth of a Burkitt's lymphoma versus disseminated invasive growth of the autologous EBV-immortalized lymphoblastoid cells and their somatic cell hybrids in SCID mice.
Walter J; Möller P; Moldenhauer G; Schirrmacher V; Pawlita M; Wolf J
Int J Cancer; 1992 Jan; 50(2):265-73. PubMed ID: 1309726
[TBL] [Abstract][Full Text] [Related]
13. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
14. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
15. The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.
Steel CM; Morten JE; Foster E
IARC Sci Publ; 1985; (60):265-92. PubMed ID: 2998993
[TBL] [Abstract][Full Text] [Related]
16. [Invasive, metastatic growth of lymphoblastoid B cells in immunodeficient SCID mice].
Walter J; Wolf J; Pawlita M; Schirrmacher V; Moldenhauer G; Möller P
Verh Dtsch Ges Pathol; 1991; 75():224-8. PubMed ID: 1724838
[TBL] [Abstract][Full Text] [Related]
17. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
[TBL] [Abstract][Full Text] [Related]
18. Burkitt's lymphoma cell line bearing surface IgA and negative for nuclear antigen of Epstein-Barr virus (EBNA).
Hayashi Y; Matsumura Y; Nishihira T; Watanabe I; Ohi R; Kasai M; Kumagai K; Kamada N
Jpn J Exp Med; 1980 Dec; 50(6):423-34. PubMed ID: 6268866
[TBL] [Abstract][Full Text] [Related]
19. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
20. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
